Travere Therapeutics came into this Q3 2026 print with a bruised chart, down over 21% in the past three months, yet the immediate verdict was muted. The stock ticked up only 0.5% to US$49.48 after the release, a cautious nod from a market that has treated the story as high promise and high risk.
The numbers tell a sharper tale. Total revenue reached US$224.6m, powered primarily by FILSPARI, while the company still reported a net loss of US$61.0m. That mix of strong kidney drug sales alongside a widening earnings hit is the expectation gap every Travere watcher now has to wrestle with.
Love Travere Therapeutics’ FILSPARI revenue engine but uneasy about the ongoing net losses and earnings hit? Screen for kidney and healthcare names that pair strong product traction with sturdier balance sheets using the list of solid balance sheet and fundamentals stocks (24 results)
Q3 2026 Earnings Summary
- Total Revenue (Q3 2026 vs Q3 2025): US$224.6m vs. US$164.9m (higher top line year on year)
- Net Income/Loss (Q3 2026 vs Q3 2025): loss of US$61.0m vs. profit of US$25.7m (moved from profit to loss)
- Basic EPS (Q3 2026 vs Q3 2025): loss of US$0.65 per share vs. earnings of US$0.29 per share (shift from positive to negative EPS)
- Earnings from Discontinued Operations (Q3 2026 vs Q3 2025): gain of US$8.7m vs. no reported contribution (discontinued items provided a small earnings offset)
Travere is already nearing $1B annualized FILSPARI sales from IgAN and FSGS. Ask Charlie what makes Travere sure FILSPARI can hit $3B.
Travere’s Bull Story Meets Concrete Milestones
The bullish view hangs on Travere Therapeutics turning FILSPARI into a cornerstone kidney franchise while seeding a fuller rare disease portfolio.
"Bullish analysts expect Travere Therapeutics to convert FILSPARI’s position as a foundational rare kidney therapy and the early FSGS launch into a durable leadership role in rare kidney and metabolic diseases."
Q3 offers real proof points. FILSPARI delivered about US$200.2m of U.S. net product sales and remains the most prescribed branded IgA nephropathy drug, with early FSGS uptake broadening. New patent coverage into 2037, active Phase 3 HARMONY enrollment, and a planned civorebrutinib IND keep the leadership ambition grounded in tangible progress, even as the firm still reports a net loss.
One Narrative disagrees with today's price. → See where this Narrative says Travere Therapeutics should trade.
Travere Bear Case: Spending Bite Now, Payoff Still Distant
Bears argue Travere Therapeutics is overspending long before diversification arrives.
"Although Travere is investing to build a broader rare disease platform with pegtibatinase and civorebrutinib, the resumption of the Phase 3 HARMONY study with topline data not expected until the second half of 2027 means elevated R&D and SG&A outlays of US$156.4 million in a single quarter could persist for several years before any incremental revenue contribution. This may weigh on GAAP profitability."
The Q3 2026 print largely supports that concern. Travere posted a GAAP net loss of US$61.0m despite US$224.6m in revenue and roughly US$200.2m from FILSPARI. Heavy operating spend, upfront licensing and no new revenue streams yet from pegtibatinase or civorebrutinib kept earnings firmly in the red, so the profitability milestone is still missing.
Hunt For Mispriced Earnings Power
Travere Therapeutics just showed how a strong revenue story can still coexist with stubborn losses. The real opportunity could sit in stocks that look misaligned before the market closes that gap.
- Company 1 - 33% below our estimate - powers compute racks that support AI-focused data centers customers are rapidly retooling.
- Company 2 - 45% below our estimate - builds an aviation aftermarket platform where newly acquired repair shops and OEM deals add higher-margin service work.
- Company 3 - 29% below our estimate - runs a digital bank expanding revenue per active customer as credit products scale across a low-cost user base.
That is three of the list. See every one of the 35 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com